J&J says Invokana is the only oral diabetes treatment to reduce the risk of these cardiovascular events and is hoping that the new indication will help reverse a steep slide in sales of the drug ...

Invokana was the first SGLT2 inhibitor to reach ... product was linked to an increased risk of lower limb amputation. The drug promptly went into reverse, with sales coming in at $738 million ...

Question: My insurance doesn’t cover my Invokana in 2025. What should I do? Answer: Each year as you evaluate insurance products, one of the primary factors you need to consider is the prescription ...